EUVIMEDEUVIMED entdecken
Open Access

PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity

Neus Martínez-Bosch iD, Noemí Manero-Rupérez, Núria Vázquez-Bellón iD, Bennett Nickell-Hernández iD, Cristina Ventura-Blanch iD, Nura Lutfi iD, Carmen G Lechuga iD, Carlos Martínez iD, Mireia Moreno iD, Coral Ampurdanés iD, Etna Abad iD, Mar Iglesias iD und 7 weitere

Science Advances · 2026

DOI: 10.1126/sciadv.adu8849 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Neus Martínez-Bosch und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Program, Hospital del Mar Research Institute (HMRI), Unidad Asociada IIBB-CSIC, Barcelona, Spain. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerases, Genomic Instability, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Ministerio de Ciencia, Innovación y Universidades, Ministerio de Ciencia, Tecnología e Innovación Productiva, CRIS Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer represents one of the most lethal tumors, characterized by an immunosuppressive microenvironment and a lack of cytotoxic immune cell infiltrates, which confer resistance to immunotherapy. Here, we demonstrate that deletion of poly(ADP-ribose) polymerase 2 (PARP2) in a Myc -driven mouse model of pancreatic cancer delays tumor progression and increases survival. Mechanistically, PARP2 loss induces enrichment of pathways associated with genomic instability and replicative stress, leading to increased γH2AX, chromosomal instability, and micronuclei accumulation. In addition to these tumor-intrinsic effects, PARP2 deletion reshapes the tumor microenvironment, promoting infiltration of cytotoxic T and natural killer cells while reducing immunosuppressive cell populations, enhancing antitumor cytotoxicity. These findings are recapitulated in a Kras G12D -driven orthotopic pancreatic ductal adenocarcinoma model. Collectively, our data support selective PARP2 inhibition as a promising therapeutic strategy for pancreatic cancer by impairing genome integrity and boosting antitumor immune response, thereby opening potential avenues for combating this devastating disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) PolymerasesGenomic InstabilityPancreatic NeoplasmsCarcinoma, Pancreatic DuctalAnimalsMiceDisease ProgressionTumor MicroenvironmentMice, KnockoutHumansKiller Cells, NaturalDisease Models, AnimalT-Lymphocytes, CytotoxicCell Line, Tumor

Substanzen

Poly(ADP-ribose) PolymerasesParp2 protein, mouse

Autor:innen und Institutionen

  • Cancer Research Program, Hospital del Mar Research Institute (HMRI), Unidad Asociada IIBB-CSIC, Barcelona, Spain.
  • Cancer Research Program, Hospital del Mar Research Institute (HMRI), Barcelona, Spain.
  • Institute of Biomedical Research of Barcelona (IIBB-CSIC), Barcelona, Spain.
  • PhD Program in Biomedicine, Facultat de Medicina (Campus Clínic), Universitat de Barcelona, Barcelona, Spain.
  • Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
  • Centro de Investigación Biomédica en Red Cancer (CIBERONC), Madrid, Spain.

ORCID-Profile: Neus Martínez-Bosch, Núria Vázquez-Bellón, Bennett Nickell-Hernández, Cristina Ventura-Blanch, Nura Lutfi, Carmen G Lechuga, Carlos Martínez, Mireia Moreno, Coral Ampurdanés, Etna Abad, Mar Iglesias, María Muñoz-Escribano, Ana Janic, Meritxell Rovira, Gabriel A Rabinovich, José Yélamos, Pilar Navarro

Förderung

  • Ministerio de Ciencia, Innovación y Universidades
  • Ministerio de Ciencia, Tecnología e Innovación Productiva
  • CRIS Cancer Foundation
  • Asociación Cáncer de Páncreas & Asociación Española de Pancreatología
  • Sales and Baron Foundations
  • Ramón y Cajal Research Fellowship

Zitieren

APA

Martínez-Bosch, N., Manero-Rupérez, N., Vázquez-Bellón, N., Nickell-Hernández, B., Ventura-Blanch, C., Lutfi, N., Lechuga, C. G., Martínez, C., Moreno, M., Ampurdanés, C., Abad, E., Iglesias, M., Muñoz-Escribano, M., Janic, A., Rovira, M., Guerra, C., Rabinovich, G. A., Yélamos, J., & Navarro, P. (2026). PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. Science Advances. https://doi.org/10.1126/sciadv.adu8849

Vancouver

Martínez-Bosch N, Manero-Rupérez N, Vázquez-Bellón N, Nickell-Hernández B, Ventura-Blanch C, Lutfi N, et al. PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity. Science Advances. 2026. doi:10.1126/sciadv.adu8849

BibTeX
@article{MartnezBosch2026,
  author = {Martínez-Bosch, Neus and Manero-Rupérez, Noemí and Vázquez-Bellón, Núria and Nickell-Hernández, Bennett and Ventura-Blanch, Cristina and Lutfi, Nura and Lechuga, Carmen G and Martínez, Carlos and Moreno, Mireia and Ampurdanés, Coral and Abad, Etna and Iglesias, Mar and Muñoz-Escribano, María and Janic, Ana and Rovira, Meritxell and Guerra, Carmen and Rabinovich, Gabriel A and Yélamos, José and Navarro, Pilar},
  title = {PARP2 deficiency impairs pancreatic cancer progression by promoting genomic instability and antitumor immunity},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.adu8849}
}
Kostenlos starten →